MorphoSys and Celgene have formed a strategic alliance to co-develop a fully human monoclonal antibody, MOR202, for patients with multiple myeloma (MM) globally and to then co-promote the results in Europe.
A Human Combinatorial Antibody Library (HuCAL) antibody targeting CD38 to treat patients with MM and certain leukemias, MOR202 is currently being evaluated in a Phase I/IIa trial in patients with relapsed or refractory myeloma.
Go deeper with GlobalData
The collaboration is focused on advancing MOR202 for patients with multiple myeloma and other indications by sharing the costs on a 1/3:2/3 basis.
Celgene haematology and oncology executive vice president and global head Mark Alles said, "This collaboration with MorphoSys enables us to rapidly advance a promising therapeutic antibody in a disease where significant progress is being made, but where patients continue to need new treatment options."
According to the deal, Celgene will make an upfront license fee of €70.8m ($92m) to MorphoSys and will invest €46.2m ($60m) to subscribe for new shares of the latter.
The transaction is subject to receipt of approval from the US antitrust authorities under the Hart-Scott-Rodino Act.
Retaining a 50/50 profit sharing in its co-promotion territory, MorphoSys is eligible for additional development, regulatory and sales milestones, in addition to sales-based royalties outside the co-promotion territory.
MorphoSys chief development officer Dr Arndt Schottelius said, "MOR202 has become a very attractive asset in our proprietary portfolio and the target CD38 is a validated highly promising target for patients with multiple myeloma."
The total potential value of the transaction is expected to be approximately €628m ($818m), assuming all development, regulatory and sales milestones are achieved.
